WilmerHale Reps Disarm Therapeutics in $30M Series A Financing
On September 19, 2017, Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing. The round was led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures. Disarm was co-founded, seeded and incubated in 2016 by Atlas Venture, together with Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis.
Read Disarm's press release for more information.